Your session is about to expire
← Back to Search
Cholinesterase Inhibitor
Echothiophate Iodide for Near-sightedness
Phase 4
Waitlist Available
Led By Stephen A Mathias, MD, MPH
Research Sponsored by Danbury Eye Physicians & Surgeons, PC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Study Summary
The purpose of this study is to test the hypothesis that myopia progression can be slowed or prevented by low dose Echothiophate Iodide.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Refractive Errors
Secondary outcome measures
Axial Length
Choroiditis
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Echothiophate IodideExperimental Treatment1 Intervention
Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
Group II: Carboxymethylcellulose Sodium (0.5%)Placebo Group1 Intervention
Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
Find a Location
Who is running the clinical trial?
Danbury Eye Physicians & Surgeons, PCLead Sponsor
Stephen A Mathias, MD, MPHPrincipal InvestigatorDanbury Eye Physicians & Surgeons, PC
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger